RELAX-AHF shows first positive findings in HFpEF patients

Serelaxin may be more effective for relieving dyspnea in heart failure with preserved ejection fraction than reduced during the first 24 hours, according to results from RELAX-AHF presented in today’s late breaking trial session1 at the Heart Failure Congress 2013. Results were also presented from VIVIDD, the first trial of the anti-diabetes drug vildagliptin in patients with heart failure.

Fuente : http://www.eurekalert.org/pub_releases/2013-05/eso…